Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size, Share & Trends Analysis Report By Product (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others), By Applications (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Others), By End Use, By Region, and Segment Forecasts - 2035

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Overview

The global pharmacogenomics technology & theranostics & companion diagnostics (cdx) market size was valued at USD 11001.91 million in 2025 and is projected to grow from USD 12619.19 million in 2026 to USD 42803.36 million by 2035, exhibiting a CAGR of 14.7% during the forecast period.

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size is expanding due to more than 350 FDA-approved drugs containing pharmacogenomic labeling as of 2024. Over 45% of oncology drugs approved in the last 5 years require companion diagnostics. More than 70% of late-stage oncology pipelines include biomarker-driven strategies, strengthening the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth trajectory. Globally, over 2.3 million genetic tests are performed annually for therapy selection, while approximately 60% of targeted cancer therapies rely on molecular profiling. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Analysis indicates that next-generation sequencing panels are used in over 55% of advanced tumor diagnostics.

In the United States, over 1.9 million new cancer cases were diagnosed in 2023, with approximately 65% undergoing molecular testing prior to therapy selection. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share in the U.S. is driven by more than 120 FDA-cleared companion diagnostic assays. Over 80% of major oncology centers utilize NGS-based panels, and more than 50 states have precision medicine initiatives supporting genetic testing reimbursement policies. Around 75% of large hospital networks integrate pharmacogenomic data into electronic health records, reinforcing the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Outlook.

 Key Findings

• Key Market Driver:Over 70% biomarker-linked oncology pipelines, 65% molecular testing adoption in cancer care, 45% of new oncology approvals requiring CDx, 60% targeted therapy reliance, 55% NGS penetration, 50% hospital integration of pharmacogenomics, 40% increase in precision medicine trials, 35% expansion in genomic testing panels.
• Major Market Restraint:Approximately 30% limited reimbursement coverage, 25% high testing infrastructure cost barriers, 40% variability in regulatory pathways, 20% lack of clinician genomic training, 35% regional disparities in molecular testing, 28% data interpretation challenges, 32% limited rural diagnostic access.
• Emerging Trends:Over 50% adoption of liquid biopsy CDx, 45% shift toward multi-gene panels, 60% AI-assisted genomic analytics growth, 35% increase in decentralized clinical trials, 48% expansion in RNA-based diagnostics, 52% integration of digital pathology platforms.
• Regional Leadership:North America holds approximately 42% market share, Europe 28%, Asia-Pacific 22%, Middle East & Africa 8%, with over 65% of global CDx approvals originating in North America and 55% of biomarker-driven trials conducted across U.S. and EU regions.
• Competitive Landscape:Top 5 companies account for nearly 58% market share, top 2 players control approximately 32%, over 120 active CDx developers globally, 40% partnerships between pharma and diagnostics firms, 35% co-development agreements in oncology.
• Market Segmentation:Oncology applications represent nearly 62%, PCR technologies 30%, sequencing 35%, immunohistochemistry 18%, in-situ hybridization 10%, neurological disorders 8%, cardiovascular 7%, immunological disorders 9%, others 14%.
• Recent Development:Over 25 new CDx approvals between 2023–2025, 40% expansion in multi-biomarker panels, 30% increase in liquid biopsy assays, 20% rise in AI-driven genomic interpretation tools, 50% growth in pharmaceutical-diagnostic co-development projects.

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Latest Trends

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends indicate that more than 55% of oncology diagnostic workflows now incorporate next-generation sequencing panels analyzing 50–500 genes simultaneously. Liquid biopsy adoption increased by approximately 30% between 2022 and 2024, with circulating tumor DNA assays used in nearly 40% of advanced cancer monitoring programs. Over 60% of clinical trials in oncology utilize at least 1 biomarker-based inclusion criterion, strengthening the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth.

Artificial intelligence-driven genomic analytics platforms are integrated in nearly 45% of molecular pathology laboratories, reducing data interpretation time by 25%. Digital pathology systems are deployed in over 35% of large diagnostic networks, improving slide analysis efficiency by 20%. In Europe, more than 70% of precision oncology centers use companion diagnostics for therapy stratification. Asia-Pacific has seen a 28% increase in hospital-based molecular laboratories since 2021. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Insights show over 100 biomarker-specific tests in oncology and more than 20 in rare diseases.

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Dynamics

DRIVER

Rising demand for precision oncology and targeted therapies.

Over 2 million new cancer diagnoses annually globally are driving biomarker testing adoption in approximately 65% of cases. More than 45% of oncology drugs approved in the past 5 years require companion diagnostics. Around 70% of late-stage oncology trials incorporate genomic stratification, while 55% of metastatic cancer patients undergo NGS-based profiling. Precision oncology programs exist in over 80% of major academic hospitals in developed regions. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Opportunities expand as 60% of immunotherapy regimens require predictive biomarker testing prior to initiation.

RESTRAINT

High infrastructure and validation costs.

Molecular diagnostic laboratories require capital equipment exceeding 5 major platforms per facility, and approximately 30% of mid-sized hospitals lack full NGS capabilities. Around 25% of reimbursement claims for advanced genomic testing face delays or partial approvals. Regulatory approval timelines may extend beyond 24 months in 40% of cases. Over 20% of pathology centers report shortages of trained molecular geneticists, limiting scalability. Data storage requirements for genomic sequencing have increased by nearly 35% annually, creating additional infrastructure burdens.

OPPORTUNITY

Expansion into non-oncology therapeutic areas.

Neurological pharmacogenomic testing accounts for approximately 8% of total CDx applications, while cardiovascular pharmacogenomics represents nearly 7%. Over 30% of antidepressant prescriptions could benefit from genetic testing, and 15% of anticoagulant dosing decisions involve pharmacogenetic markers. More than 20 immunological disorders now have validated biomarker pathways. Asia-Pacific has expanded rare disease genetic screening programs by 25% since 2022. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast highlights over 50 pipeline CDx candidates targeting autoimmune and metabolic diseases.

CHALLENGE

Data interpretation complexity and regulatory harmonization.

NGS panels can generate over 1,000 variants per patient, with approximately 10% classified as variants of unknown significance. Around 40% of global markets follow distinct regulatory frameworks, increasing approval complexity. Cross-border harmonization gaps affect nearly 30% of multinational CDx launches. Over 35% of clinical laboratories report interoperability issues between genomic software and hospital IT systems. Patient data privacy regulations impact nearly 50% of genomic data-sharing collaborations.

Segmentation Analysis

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Analysis is segmented by type and application, with sequencing technologies holding approximately 35% share, PCR around 30%, immunohistochemistry 18%, in-situ hybridization 10%, and others 7%. Oncology applications account for nearly 62% of total demand, followed by immunological disorders at 9%, neurological disorders 8%, cardiovascular disease 7%, and others 14%, reflecting strong oncology dominance in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share.

By Type

PCR:PCR-based CDx accounts for nearly 30% of total test volume, with over 500 validated PCR assays globally. Approximately 70% of hospital laboratories maintain real-time PCR systems. Turnaround times average 4–6 hours, supporting rapid mutation detection in 60% of lung cancer EGFR testing cases.

In-situ Hybridization:In-situ hybridization represents about 10% of market share, primarily in HER2 and ALK testing, with over 200 validated probes. Approximately 80% of breast cancer HER2 assessments use ISH or IHC-based methods, supporting more than 1 million annual diagnostic procedures globally.

Immunohistochemistry:Immunohistochemistry holds around 18% share, with over 300 FDA-cleared antibodies for predictive biomarker detection. PD-L1 testing alone accounts for nearly 40% of IHC-based CDx procedures, applied in more than 50% of immunotherapy eligibility screenings.

Sequencing:Sequencing technologies represent approximately 35% market share, with panels analyzing 50–500 genes per test. Over 55% of comprehensive cancer centers deploy NGS routinely. Sequencing depth averages 500x coverage in oncology diagnostics.

Others:Other technologies account for roughly 7%, including microarrays and mass spectrometry platforms. Over 150 microarray-based pharmacogenomic panels are commercially available, supporting multi-gene profiling across 20+ therapeutic categories.

By Application

Oncology:Oncology dominates with nearly 62% share, with over 45% of new oncology drugs requiring CDx. More than 65% of metastatic cancer patients undergo biomarker testing before therapy.

Neurological Disorders:Neurological applications account for approximately 8%, with pharmacogenomic testing influencing 30% of antidepressant prescriptions and 20% of epilepsy drug dosing adjustments.

Cardiovascular Disease:Cardiovascular applications represent nearly 7%, with CYP2C19 genotyping guiding 25% of antiplatelet therapy decisions in developed markets.

Immunological Disorders:Immunological disorders hold around 9%, with over 20 biomarker-linked biologics requiring diagnostic stratification.

Others:Other applications contribute 14%, including rare diseases, infectious diseases, and metabolic disorders, with more than 50 active biomarker-based therapy pipelines.

Regional Outlook

• North America accounts for approximately 42% market share, Europe 28%, Asia-Pacific 22%, Middle East & Africa 8%, with over 65% of CDx approvals originating in North America.

North America

North America holds approximately 42% of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share, supported by over 120 FDA-approved companion diagnostics. More than 80% of academic oncology centers utilize NGS panels. Approximately 65% of cancer patients undergo molecular profiling before therapy. Over 75% of pharmaceutical-CDx partnerships are headquartered in the U.S. Clinical trial biomarker integration exceeds 70% in oncology programs.

Europe

Europe accounts for nearly 28% market share, with over 50 EMA-approved companion diagnostics. Around 60% of Western European oncology centers perform routine genomic testing. Germany, France, and the UK contribute over 65% of regional testing volumes. Approximately 40% of EU-funded research programs focus on precision medicine initiatives.

Asia-Pacific

Asia-Pacific holds about 22% share, with China, Japan, and South Korea representing nearly 70% of regional activity. Molecular diagnostic laboratories in the region increased by 28% since 2021. Japan has approved over 30 CDx assays, while China supports more than 100 biomarker-driven oncology trials.

Middle East & Africa

Middle East & Africa represent around 8% market share, with over 15 national precision medicine initiatives launched since 2020. Approximately 35% of tertiary hospitals in GCC countries offer molecular oncology testing. South Africa accounts for nearly 40% of sub-Saharan molecular diagnostic activity.

List of Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Companies

• Qiagen NV
• F Hoffmann La Roche
•  

Qiagen NV and F Hoffmann La Roche collectively account for approximately 32% market share, with each holding near 16%. Together they support over 80 FDA-approved or CE-marked companion diagnostic assays and participate in more than 60 active co-development programs globally.

Investment Analysis and Opportunities

Global precision medicine funding exceeded 40 major government initiatives across 25 countries. Over 50 pharmaceutical-CDx co-development agreements were signed between 2023 and 2025. Approximately 35% of biotech venture investments targeted genomics platforms. More than 100 biomarker-driven trials entered Phase II and III stages during 2024. Asia-Pacific saw a 28% increase in molecular lab infrastructure investments. Over 60% of oncology R&D pipelines include diagnostic partnerships. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Opportunities continue expanding as 45% of pipeline therapies require patient stratification testing prior to regulatory submission.

New Product Development

Between 2023 and 2025, over 25 new CDx assays were approved globally. Multi-gene NGS panels expanded by 40%, with panels now analyzing up to 500 genes per test. Liquid biopsy CDx assays increased by 30%, covering over 15 actionable mutations in a single workflow. AI-powered genomic interpretation tools reduced analysis time by 25% across 45% of major labs. Over 20 RNA-based diagnostics entered validation phases. Digital pathology systems integrating CDx increased deployment by 35%. More than 10 companies introduced fully automated sample-to-result platforms, reducing turnaround times by 20%.

Five Recent Developments (2023–2025)

1. Over 10 new oncology CDx approvals linked to immunotherapy drugs.
2. 30% increase in liquid biopsy assay launches targeting 15+ mutations.
3. 20% expansion in AI-based genomic data interpretation platforms.
4. More than 5 large pharma-diagnostic co-development agreements signed annually.
5. 40% growth in multi-biomarker panel adoption across tertiary cancer centers.

Report Coverage of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Research Report covers over 25 countries across 4 major regions, analyzing more than 120 approved companion diagnostics and 200 pipeline biomarker-linked therapies. The report evaluates 5 technology segments and 5 application categories, representing nearly 95% of current clinical CDx utilization. Over 300 clinical trials incorporating companion diagnostics are assessed. Regulatory frameworks across 15 major markets are examined. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Report includes analysis of over 50 strategic partnerships formed between 2023 and 2025, highlighting 60% oncology dominance and 35% sequencing technology penetration within the global market landscape.